Work

516P Co-mutational analysis of lung carcinoma across early and advanced stages: Evidence from the LANTERN project cohort

Year: 2026

Type: article

Abstract: Biomarker testing is essential for identifying lung cancer (LC) patients with actionable oncogenic drivers. In this perspective, early stage settings remain less explored. Co-occurring mutations involving established drivers (eg, EGFR) may modulate responses to targeted therapies. This study aimed to define the complex co-mutational landscape of LC and highlight stage-specific differences from the large cohort the LANTERN study.

Source: ESMO Open

DOI: 10.1016/j.esmoop.2026.106831

Authors: J. Evangelista, E. De Paolis, D. Dalfovo, C. Sassorossi, A. Campanella, A. Cancellieri, E. Vita, A. Piermattei, L. Boldrini, E.G.C. Troost, S. Löck, N. Farré, E. Ozturk, R. Trisolini, E. Bria, A. Urbani, S. Margaritora, A. Minucci, F. Lococo

Institutions: Agostino Gemelli University Polyclinic, Helmholtz-Zentrum Dresden-Rossendorf, OncoRay, University Hospital Carl Gustav Carus, Technische Universität Dresden, Istituti di Ricovero e Cura a Carattere Scientifico, Hospital Del Mar, Parc de Salut, Koç University

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,910

OpenAlex ID: W7138347927

FWCI:

Cites:

Cited by:

Related to: